Loading
BrYet is developing ML-016, a form of the chemotherapy drug doxorubicin packed into tiny silicon particles meant to deliver it to cancer that has spread to the lungs or liver. It began an early trial in Australia in 2026.
BrYet US, Inc., at 2450 Holcombe Boulevard, Houston, Texas, is a privately owned company led by president and chief executive Mauro Ferrari that develops treatments for primary and metastatic cancers of the lungs and liver. Its platforms are Transport Oncophysics, a mathematical framework for predicting how injected drugs move and distribute in tumours, and nanoporous silicon microparticles that bio-erode into silicic acid; it holds its own patents and some licensed from Houston Methodist Research Institute and the University of Texas Health Science Center at Houston. The lead product ML-016 (iNPG-pDox) is an injectable nanoparticle generator: an amino acid polymer conjugated to doxorubicin, formulated with mesoporous silicon elements that target tumour blood vessels and release the conjugate as exosome-like vesicles. Preclinical work cited by the company used metastatic triple-negative breast cancer and soft tissue sarcoma lung metastasis models. The company announced Australian ethics approval for a first-in-human phase 1/2 trial in advanced cancers with lung or liver involvement in October 2025, filed a US IND in March 2026, and in September 2026 announced approval of a cGMP manufacturing line for ML-016 to supply the Australian study. Its first registered cancer trial, NCT07723482, was posted on ClinicalTrials.gov in July 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/